BioNotebook: Seven deals, an extension and a delay; Regulus/Biogen, Theraclone/Gilead, Ignyta/Nerviano, Affiris/MJFF and more
This article was originally published in Scrip
Executive Summary
From the earliest stages of drug development to commercialization, biotechnology companies have been busy this summer with many closing deals in the midst of second quarter earnings season.